cas 2162-31-4|| where to buy THP-PEG1-alcohol

Название продукции:THP-PEG1-alcohol

IUPAC Name:2-(oxan-2-yloxy)ethan-1-ol

Упаковочная единица	Доступно для заказа	Цена ($)
CM339352-5g	in stock	Ƕũ
CM339352-10g	in stock	ƥȡȐ
CM339352-25g	in stock	ƿŵȐ

Только для использования в НИОКР..

Форма запроса

Химическое название

Номер CAS

Количество*

Необходимые спецификации*
(% пробы, категория материала и т.д.)

Контактное лицо*

Электронная почта*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 2162-31-4 regularly via the above email.

Дополнительные примечания

Verification code*

refresh

: Номер CAS:2162-31-4; Молекулярная формула:C7H14O3; Точка плавления:-; Smiles-код:OCCOC1OCCCC1; Плотность:

: Номер в каталоге:CM339352; Молекулярная масса:146.19; Точка кипения:; Номер Mdl:MFCD00185588; Хранение:

: PROTAC-Linkers; PROTACs (Proteolytic Targeting Chimeric Molecules) are heterobifunctional protein degraders and are promising targeted therapy candidates for cancer. PROTAC is composed of three parts, one end is connected with the ligand bound by E3 ligase, the other end is connected with the ligand bound by the target protein, and the middle is the linker.; Protac Linkers; where to buy PROTAC-Linkers, Chemenu is research-based manufacturer of pharmaceutical intermediates. We supply Protac Linkers with low price.Warmly welcome new and old customers to visit!

: Naporafenib; Erasca's Naporafenib receives FDA Fast Track Designation in combination with Trametinib (Mekinist) for the treatment of adult patients with advanced NRAS-mutated melanoma. Naporafenib has been dosed in over 500 patients to date, and has demonstrated preliminary evidence of its effectiveness. Naporafenib (LXH254) is an orally available pan-RAF inhibitor under development. It targets downstream BRAF and CRAF nodes, and has first-in-class and best-in-class potential in NRAS-mutated melanoma and other RAS/MAPK pathway-altered solid tumors.

: Onvansertib; Polo-like kinase 1 (PLK1) is a key regulator of the cell-cycle progression found in human cancers, and a potential therapeutic target for oncology drug development. The recent journal Clinical Cancer Research details the Phase 1b Study of Onvansertib in combination with chemotherapy+bevacizumab treatment for patients with patients with KRAS-mutated metastatic colorectal cancer (mCRC).
Cardiff Oncology’s novel inhibitor, Onvansertib effectively targets PLK1, that prevents from tumor cell growth. It aids restore DNA damage and promote the efficacy of the standard of care therapy in a number of indications.